可孚医疗 20260106 摘要 可孚医疗通过战略投资纽林克医疗（5.83%股权）和励智智能 （12.45%股权）布局脑机接口领域，旨在强化现有业务协同，并为未 来技术融合和产业升级奠定基础。纽林克医疗专注于植入式脑机接口技 术，尤其在仿生眼和仿生耳产品方面与可孚健耳听力业务具有协同效应。 励智智能已在脑机接口领域深耕多年，覆盖从传感器到算法的全链条， 并已取得 7 张注册证，预计 2025 年上半年完成十几至二十张注册证申 请，包括国家局审批的三类证。目前，励智智能已与全国多家医院及地 方政府合作，订单超过 5 亿元。 脑机接口技术分为侵入式和非侵入式两大类，应用场景不同。非侵入式 脑机接口在神经内科、神经外科等领域应用广泛，可孚医疗正与可孚医 疗合作，将其应用于呼吸机、睡眠仪等产品，提升产品附加值，并积极 拓展香港及东南亚等海外市场。 国家卫健委和药监局对脑机接口的认定标准包括读脑（信号获取与解 码）和控脑（信号控制输出）两个过程，双向互动是衡量产品质量的关 键。脑机接口技术在医疗领域的应用集中在骨科康复、精神科和睡眠科 等领域，与机器人配合可提升临床效果。 Q&A 可孚医疗投资脑机接口项目的缘由及具体项 ...

央视网消息：据"首都教育"公众号消息，为推动北京市科普基础设施建设，发挥科普基地的创新示范引领作用，北京市科学技术委员会、中关村科技园区 管理委员会和北京市科学技术协会共同组织开展2025年度北京市科普基地评审工作。经形式审查、专家评审、现场踏勘和社会公示，近日决定命名"北京 医学健康科普基地"等60家北京市科普基地，命名周期为2025-2027年。具体名单，一起来看↓↓↓ | 序 | 基地名称 | 管理单位 | | --- | --- | --- | | 름 | | | | 1 | 北京医学健康科普基地 | 北京大学人民医院（北京大学第二临床医学院） | | 2 | 北京集成电路与人工智能科普基地 | 中关村智能科技发展促进会 | | 3 | 北京人工智能安全科普基地 | 奇安信科技集团股份有限公司 | | 4 | 北京百姓科技实践科普基地 | 北京树思源数字媒体科技有限公司 | | 5 | 北京地质调查岩石科普基地 | 中国地质调查局自然资源综合调查指挥中心 | | e | 北京慢性病防治健康科普基地 | 北京慢性病防治与健康教育研究会 | | 7 | 北京智慧清洁能源科普基地 | 中国电建集团北京勘测设 ...

人民财讯1月7日电，1月7日，证券时报记者从微创机器人获悉，该公司依托神经元MicroGenius多模态 自主手术大模型，成功完成了全球首例"大模型自主手术"动物实验。这一突破性成果不仅填补了全球大 模型自主手术在体动物实验的技术空白，更推动全球AI产业在医疗领域的深度升级与跨界融合，此 前，在既有公开文献与实践中尚无同类先例。 ...

聚焦品质与营养，一级菜籽油解锁健康饮食新体验 此次可喜安推出的一级菜籽油，精准契合了当前消费者对健康油品的核心需求，在原料选择、加工工 艺、营养保留等方面均展现出严苛的品质把控。菜籽油作为我国产量最大的食用植物油，不仅适配中式 爆炒、煎炸等多种烹饪场景，其营养优势更是备受认可——不饱和脂肪酸含量超60%，饱和脂肪酸含量 在常见植物油中处于较低水平，且富含维生素E、植物甾醇等有益成分，其中植物甾醇有助于抑制人体 对胆固醇的吸收，维生素E则具备天然抗氧化作用，能更好地呵护心血管健康。 随着全民健康意识的觉醒，消费市场正加速向品质化、健康化转型，食用油作为饮食健康的基础环节， 其品质升级成为产业发展的核心趋势。从基础饱腹到品质安全，再到有机健康，消费者对食用油产品的 需求迭代，推动着相关企业不断探索创新。在此背景下，深耕大健康产业21年的可喜安集团再传新动态 ——正式推出一级菜籽油产品，这一举措不仅丰富了品牌健康产品矩阵，更标志着其从健康器械、智能 厨电向健康食品领域的进一步延伸，为大健康产业布局再添重要一环。此次新品的推出，既是可喜安响 应消费升级需求的精准布局，也是其构建全场景健康生态的关键一步。 深耕健康领域 ...

据交易所数据显示， 美好医疗连续三个交易日涨停，晋级3连板。该股今日于9时56分封涨停，成交额 25.97亿元，换手率16.90%。金融界App AI线索挖掘： 脑机接口领域，马斯克透露脑机接口设备量产计 划，公司正与下游脑机接口客户开展产品合作，协助实现从实验室到批量出货的商业化转化，具备将人 工耳蜗技术储备延伸至脑机接口的能力。 人工智能领域，公司家用及 消费电子事业部已结合PEEK制 造、精密 模具、 传感器技术布局 人形机器人，手术机器人产品已向部分国内外客户小批量供货。 呼吸 机领域，公司是全球家用呼吸机头部企业，2024年家用呼吸机组件收入同比增长25.58%。人工耳蜗领 域，公司是人工耳蜗CDMO市场头部企业，人工植入耳蜗组件收入同比增长18.74%，客户均为全球细 分市场龙头。风险提示：连板股波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等 公开数据生成，内容不构成投资建议。） ...

Core Insights - The U.S. stock market has reached historical highs, with the Dow Jones Industrial Average surpassing 49,000 points, indicating a significant shift in the investment environment that could present both opportunities and risks for investors [1][2]. Market Performance - On January 6, 2025, the Dow Jones increased by 484.90 points (0.99%) to close at 49,462.08, marking a new record [1]. - The S&P 500 rose by 42.77 points (0.62%) to 6,944.82, also achieving a historical closing high [1]. - The Nasdaq Composite gained 151.35 points (0.65%) to reach 23,547.17 [1]. - The Dow Jones had already increased by 1.23% on January 5, leading to a cumulative rise of over 2% in just two days [2]. Economic Drivers - The first driving force behind the stock market surge is the Federal Reserve's monetary policy, which has lowered interest rates to a range of 3.50% to 3.75% by 2025, increasing liquidity in the market [2]. - The second factor is corporate stock buybacks, which have reached near-historical highs, reducing the number of shares and pushing stock prices higher [2]. - The third influence is the AI boom and the self-reinforcing nature of passive investments, where rising large-cap stocks lead to increased index fund purchases, further driving prices up [3]. Valuation Concerns - The Buffett Indicator, which measures the ratio of total stock market capitalization to GDP, has reached 223%, significantly exceeding the 70%-80% range considered reasonable [3]. - Historical data shows that after two consecutive years of over 10% gains in the S&P 500, the following year typically sees a decline [3]. Diverging Opinions - Optimists argue that AI profits have yet to be fully realized, and the U.S. economy has not faced a hard landing, with S&P 500 earnings growing by 13.4% year-over-year in Q3 2025 [4]. - Pessimists highlight the high valuations based on uncertain economic conditions, warning that any negative developments could lead to a market correction [4][5]. Global Investment Trends - Analysts suggest that the trend of global capital moving towards Asia will continue, driven by a weakening dollar, significant valuation differences, and higher economic growth rates in China compared to the U.S. [6]. - The S&P 500's TTM P/E ratio is 29.5, while the CSI 300 is at 14.1, indicating a higher safety margin in the Chinese market [6]. Investment Opportunities - Key sectors to watch include hard technology, high-end manufacturing, and structural opportunities in domestic demand, particularly in aging-related and emotional value consumption sectors [8]. - Companies with core technologies and those benefiting from domestic trends are expected to attract investment [8]. Conclusion - The current market dynamics suggest that investors should focus on structural opportunities in Asia, particularly in undervalued sectors with strong growth potential, rather than chasing high valuations in the U.S. market [10].

Core Viewpoint - The medical device industry is currently in a challenging phase, with "endurance" being a key theme. Leading companies are proactively adjusting their strategies, including product structure changes and international expansion, as seen with Mindray Medical [1][3]. Group 1: Company Strategies - Mindray Medical is increasing the proportion of in vitro diagnostic (IVD) products in its overall revenue while decreasing the share of life information and support products and medical imaging products [1]. - The company aims to shift from traditional medical equipment sales to a more sustainable consumable-driven business model through IVD products [1]. - As of mid-2025, Mindray's overseas revenue share rose to 49.77%, up from 39.59% in mid-2022, indicating a strong push for international market penetration [3]. Group 2: Industry Challenges - The IVD sector is facing intense price competition and regulatory challenges domestically, making it a difficult environment for growth [3]. - The overall revenue for the A-share IVD sector declined by 14.5% year-on-year in the first three quarters of 2025, with net profit down 26.4%, marking three consecutive years of decline [8]. Group 3: Company Performance - Ji'an Medical, another key player, reported a net profit of 16.03 billion yuan in 2022, showcasing the potential of the IVD sector despite the current downturn [3]. - Ji'an Medical's overseas revenue accounted for 85.47% of total revenue by mid-2025, highlighting its successful international expansion compared to peers [8]. - Despite a 48.89% drop in total revenue to 1.069 billion yuan in the first three quarters of 2025, Ji'an Medical's net profit increased by 16.11% to 1.589 billion yuan, supported by over 1.1 billion yuan in investment income [7]. Group 4: Investment Strategies - Ji'an Medical is focusing on stable cash management and increasing investments in venture capital and private equity rather than pursuing aggressive mergers and acquisitions [7]. - The company has diversified its investment portfolio, including stakes in companies like Xiaomi and NIO, and plans to use up to 17 billion yuan for wealth management [10]. - Ji'an Medical's stock price has shown resilience, with a 9.17% increase in 2024 and a slight decline of 1.33% in 2025, outperforming industry peers [7]. Group 5: Future Outlook - Ji'an Medical's management believes that the current market valuation does not reflect the company's true value, prompting share buyback initiatives to stabilize stock prices [10]. - The company has received FDA pre-market notifications for new IVD products, which could enhance its competitive edge in the market [11]. - The overall recovery of the industry is crucial for Ji'an Medical's main business, but its dual strategy of combining medical devices with investment could provide a viable path forward during challenging times [11].

Core Viewpoint - The financial performance and trading activity of Kaili Medical indicate a mixed outlook, with revenue growth but significant decline in net profit, alongside notable changes in shareholder composition and trading volumes [1][2][3]. Group 1: Financial Performance - For the period from January to September 2025, Kaili Medical reported operating revenue of 1.459 billion yuan, representing a year-on-year increase of 4.37% [2]. - The net profit attributable to shareholders was 33.51 million yuan, showing a significant year-on-year decrease of 69.25% [2]. - Cumulative cash dividends since the company's A-share listing amount to 381 million yuan, with 258 million yuan distributed over the past three years [3]. Group 2: Trading Activity - On January 6, Kaili Medical's stock price remained unchanged, with a trading volume of 146 million yuan [1]. - The financing buy-in amount for the day was 19.69 million yuan, while the financing repayment was 13.77 million yuan, resulting in a net financing buy of 5.92 million yuan [1]. - The total balance of margin trading as of January 6 was 169 million yuan, with the financing balance accounting for 1.41% of the circulating market value, indicating a high level compared to the past year [1]. Group 3: Shareholder Composition - As of September 30, 2025, the number of shareholders increased to 16,100, a rise of 12.75% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.31% to 26,824 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 7.40 million shares, an increase of 1.72 million shares, while the Hua Bao Zhong Zheng Medical ETF reduced its holdings by 1.07 million shares [3].

Group 1 - The core viewpoint of the news is that 凯普生物 (Capbio) is experiencing a decline in stock performance and financial metrics, with significant changes in financing and shareholder structure [1][2][3] Group 2 - On January 6, 凯普生物's stock fell by 0.35%, with a trading volume of 49.52 million yuan. The financing buy amount was 2.54 million yuan, while the financing repayment was 6.87 million yuan, resulting in a net financing outflow of 4.33 million yuan [1] - As of January 6, the total balance of margin trading for 凯普生物 was 88.75 million yuan, with a financing balance of 88.71 million yuan, accounting for 2.43% of the circulating market value, which is below the 10% percentile level over the past year [1] - In terms of securities lending, on January 6, 凯普生物 repaid 600 shares and sold 1,400 shares, with a selling amount of 7,910 yuan. The remaining securities lending volume was 7,400 shares, with a balance of 41,800 yuan, also below the 50% percentile level over the past year [1] Group 3 - As of December 20, the number of shareholders for 凯普生物 was 27,400, a decrease of 0.58% from the previous period, while the average circulating shares per person increased by 0.58% to 23,172 shares [2] - For the period from January to September 2025, 凯普生物 reported operating revenue of 486 million yuan, a year-on-year decrease of 20.38%, and a net profit attributable to shareholders of -128 million yuan, reflecting a year-on-year increase of 51.25% [2] Group 4 - Since its A-share listing, 凯普生物 has distributed a total of 485 million yuan in dividends, with 193 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of 凯普生物 included a new shareholder, the Medical Device ETF (159883), holding 2.39 million shares [3]

Core Viewpoint - The company Ophthalmic Vision Technology Co., Ltd. (欧普康视) has shown a mixed financial performance with slight revenue growth but a significant decline in net profit, indicating potential challenges ahead in maintaining profitability while managing investor sentiment and market position [2][3]. Financing and Trading Activity - On January 6, the stock price of Ophthalmic Vision increased by 1.69%, with a trading volume of 463 million yuan. The financing buy-in amount for the day was 51.27 million yuan, while the financing repayment was 46.70 million yuan, resulting in a net financing buy of 457.09 thousand yuan. The total financing and securities balance reached 613 million yuan [1]. - The current financing balance of 609 million yuan accounts for 4.20% of the circulating market value, which is above the 60th percentile level over the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 900 shares were repaid, and 195,900 shares were sold short, amounting to 3.18 million yuan at the closing price. The remaining short selling volume was 269,000 shares, with a balance of 4.36 million yuan, also above the 50th percentile level over the past year [1]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 1.433 billion yuan, reflecting a year-on-year growth of 0.13%. However, the net profit attributable to shareholders decreased by 15.41% to 442 million yuan [2]. - Since its A-share listing, the company has distributed a total of 949 million yuan in dividends, with 576 million yuan distributed over the past three years [3]. Shareholder Structure - As of December 19, the number of shareholders for Ophthalmic Vision was 61,900, a slight decrease of 0.02% from the previous period. The average circulating shares per person increased by 0.02% to 10,797 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major ETFs, such as Huabao Zhongzheng Medical ETF and E Fund Growth ETF, while a new shareholder, Penghua Medical Technology Stock A, entered the top ten with 3.90 million shares [3].